DURECT Corporation

DURECT Corporation is a late-stage biopharmaceutical company based in Cupertino, California. The company employs 46 people and generates an annual revenue of $50 million. DURECT is focused on developing epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions. DURECT's therapeutic pipeline includes Larsucosterol, a lead drug candidate currently in clinical development. Larsucosterol binds to and inhibits DNA methyltransferases (DNMTs), enzymes involved in hypermethylation associated with alcohol-associated hepatitis (AH). The FDA has granted Fast Track Designation to Larsucosterol for the potential treatment of AH, and its application for non-alcoholic steatohepatitis (NASH) is also being explored. Additionally, DURECT has developed POSIMIR® (bupivacaine solution), a non-opioid analgesic utilizing its innovative SABER® platform technology. POSIMIR® is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States. DURECT's epigenetic therapies represent a novel approach to treating a range of diseases. The company's focus on DNA methylation offers the potential for targeted and effective treatment strategies. You can learn more about DURECT Corporation by visiting their website at durect.com.